There are multiple neuroimaging modalities that can track AD pathophysiology. A few are amyloid (PiB) PET, hippocampal volumes via structural MRI, and tempoparietal hypometabolism via FDG PET. There are a multitude of papers on these topics but see below for a few representative manuscripts from Cliff Jack's group at Mayo Clinic.